Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MAPK12
REST API REST API
Homo sapiens
MAPK12 is differentially expressed in 304 experiments: 120 organism parts: skeletal muscle, mammary gland, ... (118 more);, 183 disease states: normal, T cell acute lymphoblastic leukemia, ... (181 more);, 82 cell types 322 cell lines 155 compound treatments and 60 other conditions.
Synonyms SAPK-3, PRKM12, ERK6, SAPK3, p38gamma
Orthologs HOG1 (Saccharomyces cerevisiae)   MAPK12 (1 of 2) (Danio rerio)   MAPK12 (Gallus gallus)   mapk12 (Danio rerio)   Mapk12 (Mus musculus)   A5PJL3_BOVIN (Bos taurus)   Mapk12 (Rattus norvegicus)   mapk12 (Xenopus tropicalis)   MAPK12 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, cytoplasm, cell cycle arrest, protein tyrosine kinase activity, MAP kinase activity, soluble fraction, ATP binding, Ras protein signal transduction, magnesium ion binding, transferase activity, transferring phosphorus-containing groups, muscle organ development, muscle cell differentiation, nucleotide binding, protein serine/threonine kinase activity, nucleoplasm, negative regulation of cell cycle, signal transduction, protein kinase activity, mitochondrion, myoblast differentiation, DNA damage induced protein phosphorylation, nerve growth factor receptor signaling pathway, positive regulation of muscle cell differentiation, protein phosphorylation
UniProt Accession A8MY48, B5MDL5, P53778, F6TXG5
InterPro Term Tyrosine-protein kinase, catalytic domain, MAP kinase, p38, Protein kinase, catalytic domain, Serine/threonine- / dual-specificity protein kinase, catalytic domain, Serine-threonine/tyrosine-protein kinase catalytic domain
Search EB-eye ENSG00000188130
Show more properties
Experimental Factors
organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-17539, E-GEOD-3526, E-MTAB-62, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

cell line

studied in E-GEOD-3860, E-GEOD-17482, E-MEXP-1121, E-GEOD-19639, E-GEOD-18005, ... (44 experiments)

Factor Value U/D Experiments
HL-60
4
E-GEOD-5258, E-MTAB-37, E-GEOD-995, E-GEOD-24147
DU4475
2
E-MTAB-37, E-GEOD-10890
HCC1143
2
E-GEOD-10890, E-MTAB-37
HCC1395
2
E-GEOD-10890, E-MTAB-37
HCT116
2
E-GEOD-18005, E-MTAB-62
HT1080
2
E-GEOD-20089, E-GEOD-13548
316 more value(s).


cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-23806, ... (50 experiments)

Factor Value U/D Experiments
fibroblast
1
3
E-GEOD-23402, E-GEOD-13548, E-GEOD-3920, E-GEOD-3204
721 B lymphoblast
2
E-TABM-145, E-AFMX-5
endothelial cell
2
E-GEOD-3920, E-GEOD-19240
plasma cell
2
E-GEOD-6691, E-MEXP-2360
stromal cell
2
E-MEXP-2034, E-GEOD-10797
macrophage
1
2
E-GEOD-22373, E-GEOD-5099, E-MEXP-3521
76 more value(s).


disease state

studied in E-GEOD-3307, E-GEOD-16134, E-GEOD-15960, E-GEOD-1577, E-GEOD-16515, ... (55 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-GEOD-995, E-MEXP-149, E-MTAB-62
anaplastic large cell lymphoma
2
E-MTAB-62, E-GEOD-6338
non-small cell lung cancer
2
E-GEOD-18842, E-MTAB-62
embryonal rhabdomyosarcoma
1
E-MEXP-121
systemic juvenile idiopathic arthritis
1
E-GEOD-7753
juvenile idiopathic arthritis subtype systemic
1
E-GEOD-13501
177 more value(s).


Compound treatment

studied in E-GEOD-23031, E-GEOD-6907, E-MTAB-798, E-TABM-782, E-GEOD-6462, ... (27 experiments)

Factor Value U/D Experiments
none
3
8
E-GEOD-19519, E-GEOD-10890, E-GEOD-11462, E-GEOD-10313, E-GEOD-412, ... (11 experiments)
chlorpheniramine 18 micromolar
1
E-MTAB-798
chloramphenicol 450 micromolar
1
E-MTAB-798
oxidized low-density lipoprotein 200 micrograms per milliliter
1
E-GEOD-5741
fenofibrate 6 micromolar
1
E-MTAB-798
nitrosodiethylamine 2000 micromolar
1
E-MTAB-798
149 more value(s).


RNAi

studied in E-MEXP-2115, E-MEXP-2759, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Factor Value U/D Experiments
FLI1 siRNA
1
1
E-MEXP-2759
siRNA-mediated CDC7 inhibition
1
E-MEXP-2115
H1033 ASCL1 siRNA
1
1
E-MEXP-1857
Luc siRNA
1
E-GEOD-3697
SIM2s
1
E-MEXP-101
HDAC1 knockdown
1
E-GEOD-12438
6 more value(s).


age at diagnosis
studied in E-GEOD-21653

age at onset
studied in E-GEOD-21521

biosource provider
studied in E-TABM-325, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

cell treatment
studied in E-MEXP-1192

clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-9489, E-MTAB-691, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-14359, E-GEOD-7696, E-MEXP-1251, ... (11 experiments)

clinical treatment
studied in E-GEOD-6532

developmental stage
studied in E-GEOD-19743, E-MEXP-2359, E-GEOD-4667, E-GEOD-18290, E-MEXP-2283, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-6764, E-GEOD-3013 ... (5 experiments)

estrogen receptor status
studied in E-GEOD-6532

ethnicity
studied in E-GEOD-23120

genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431 ... (5 experiments)

genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-13911, E-GEOD-18005, E-GEOD-10916, ... (15 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-10315, E-MEXP-2657, E-MEXP-1446, ... (11 experiments)

histology
studied in E-TABM-234, E-GEOD-9489, E-GEOD-21653, E-GEOD-10780

immunoprecipitated protein
studied in E-GEOD-21918

individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (28 experiments)

Infection
studied in E-GEOD-8527, E-MEXP-1274, E-GEOD-13637, E-GEOD-12108, E-GEOD-12254, ... (9 experiments)

injury
studied in E-GEOD-19743

karyotype
studied in E-GEOD-7214

ki67 ihc
studied in E-GEOD-21653

labeling
studied in E-LGCL-5

light
studied in E-GEOD-1725

lymph node status
studied in E-GEOD-6532

material type
studied in E-MEXP-455, E-GEOD-9171

media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

metastasis
studied in E-GEOD-18105

molecular subtype
studied in E-GEOD-21653

organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

organism status
studied in E-GEOD-19188

performer
studied in E-GEOD-2004, E-LGCL-5

phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-5824, E-GEOD-17636, E-GEOD-5820, ... (6 experiments)

progesterone receptor status
studied in E-GEOD-6532

protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19249, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

read length
studied in E-GEOD-30222

replicate
studied in E-GEOD-15811

sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

sampling time point
studied in E-GEOD-19743, E-MTAB-798, E-GEOD-18995

sex
studied in E-GEOD-14359, E-GEOD-19069, E-GEOD-7307

stimulus
studied in E-GEOD-20114, E-GEOD-22103

strain or line
studied in E-MEXP-1996, E-TABM-125

subtype
studied in E-GEOD-24283

survival time
studied in E-GEOD-19188

test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

transfection
studied in E-GEOD-14680

treatment
studied in E-GEOD-30501, E-GEOD-33562, E-GEOD-34055, E-GEOD-21909, E-GEOD-34635, ... (6 experiments)

tumor grading
studied in E-GEOD-4290, E-GEOD-14359, E-TABM-147

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.928 secs.
 
Gene Expression Atlas 2.0.13- 4/23/12 11:55:46 AM